{"id":"carvedilol-phosphate-modified-release-formulation","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Dizziness"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Erectile dysfunction"}]},"_chembl":{"chemblId":"CHEMBL1201167","moleculeType":"Small molecule","molecularWeight":"504.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carvedilol blocks beta-1, beta-2, and alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and blood vessels. The modified-release formulation provides sustained drug delivery over 24 hours, allowing once-daily dosing. This formulation maintains the pharmacological effects of standard carvedilol while improving patient compliance.","oneSentence":"Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:59.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Left ventricular dysfunction post-myocardial infarction"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT00273052","phase":"PHASE3","title":"COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-05","conditions":"Hypertension","enrollment":514},{"nctId":"NCT00123903","phase":"PHASE3","title":"COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"Heart Failure, Congestive and Microalbuminuria","enrollment":1220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Carvedilol Phosphate modified release formulation","genericName":"Carvedilol Phosphate modified release formulation","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction post-myocardial infarction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}